EcoDrugPlus

Carbonic Anhydrase Iv C

Ensembl ID : ENSCCRG00000035677
Gene Symbol: CA4C
1 Cross references
198 Possible Orthologues:

Carbonic Anhydrase Iv C

Ensembl ID : ENSCCRG00000082655
Gene Symbol: CA4C
1 Cross references
198 Possible Orthologues:

Carbonic Anhydrase Vii

Ensembl ID : ENSCCRG00000060535
Gene Symbol: CA7
1 Cross references
219 Possible Orthologues:

Carbonic Anhydrase Vii

Ensembl ID : ENSCCRG00000067364
Gene Symbol: CA7
1 Cross references
219 Possible Orthologues:

Carbonic Anhydrase Va

Ensembl ID : ENSCCRG00000058562
Gene Symbol: CA5A
1 Cross references
228 Possible Orthologues:

Carbonic Anhydrase Va

Ensembl ID : ENSCCRG00000065075
Gene Symbol: CA5A
1 Cross references
228 Possible Orthologues:

Carbonic Anhydrase Xiv

Ensembl ID : ENSCCRG00000073224
Gene Symbol: CA14
1 Cross references
209 Possible Orthologues:

Casein Kinase 1, Epsilon

Ensembl ID : ENSCCRG00000017335
Gene Symbol: CSNK1E
1 Cross references
200 Possible Orthologues:

Casein Kinase 1, Epsilon

Ensembl ID : ENSCCRG00000017046
Gene Symbol: CSNK1E
1 Cross references
199 Possible Orthologues:

Caspase 9, Apoptosis-Related Cysteine Peptidase

Ensembl ID : ENSCCRG00000019120
Gene Symbol: CASP9
1 Cross references
201 Possible Orthologues:

Caspase 9, Apoptosis-Related Cysteine Peptidase

Ensembl ID : ENSCCRG00000015795
Gene Symbol: CASP9
1 Cross references
201 Possible Orthologues:

Catechol-O-Methyltransferase A

Ensembl ID : ENSCCRG00000025764
Gene Symbol: COMTA
1 Cross references
164 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).